Crucell and DSM Announce Licensing and Service Agreement with Roche for Protein Production

17-Feb-2005

Crucell N.V. and allied contract manufacturer DSM Biologics announced that they have signed a PER.C6® research license agreement with Roche. This license agreement allows Roche to use the PER.C6® cell line for production of monoclonal antibody products as well as a specific undisclosed protein.

Roche has selected PER.C6® for this particular protein because it believes PER.C6® possesses unique features capable of delivering the appropriate product quality. Further to this agreement, Crucell will work with Roche in creating a production clone for the specific protein.

Under the terms of the agreement, Roche will pay a research license payment, annual maintenance fees, and research funding. Further financial details were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances